233 related articles for article (PubMed ID: 8154880)
21. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain.
Yamada M; Yamada M; Richelson E
Neuroscience; 1995 Jan; 64(2):405-17. PubMed ID: 7700529
[TBL] [Abstract][Full Text] [Related]
22. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
[TBL] [Abstract][Full Text] [Related]
23. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
24. An altered histaminergic innervation of the substantia nigra in Parkinson's disease.
Anichtchik OV; Rinne JO; Kalimo H; Panula P
Exp Neurol; 2000 May; 163(1):20-30. PubMed ID: 10785440
[TBL] [Abstract][Full Text] [Related]
25. Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons.
Counihan TJ; Landwehrmeyer GB; Standaert DG; Kosinski CM; Scherzer CR; Daggett LP; Veliçelebi G; Young AB; Penney JB
J Comp Neurol; 1998 Jan; 390(1):91-101. PubMed ID: 9456178
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
27. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
28. Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain.
Cerruti C; Walther DM; Kuhar MJ; Uhl GR
Brain Res Mol Brain Res; 1993 Apr; 18(1-2):181-6. PubMed ID: 8479287
[TBL] [Abstract][Full Text] [Related]
29. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
Sedaghat K; Finkelstein DI; Gundlach AL
Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193
[TBL] [Abstract][Full Text] [Related]
30. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
31. Functional activity of zona incerta neurons is altered after nigrostriatal denervation in hemiparkinsonian rats.
Périer C; Vila M; Féger J; Agid Y; Hirsch EC
Exp Neurol; 2000 Mar; 162(1):215-24. PubMed ID: 10716902
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism.
Rothblat DS; Schroeder JA; Schneider JS
J Neurosci Res; 2001 Aug; 65(3):254-66. PubMed ID: 11494360
[TBL] [Abstract][Full Text] [Related]
33. Dopamine transporter immunoreactivity in rat brain.
Freed C; Revay R; Vaughan RA; Kriek E; Grant S; Uhl GR; Kuhar MJ
J Comp Neurol; 1995 Aug; 359(2):340-9. PubMed ID: 7499533
[TBL] [Abstract][Full Text] [Related]
34. Co-expression of dopamine transporter mRNA and tyrosine hydroxylase mRNA in ventral mesencephalic neurones.
Augood SJ; Westmore K; McKenna PJ; Emson PC
Brain Res Mol Brain Res; 1993 Dec; 20(4):328-34. PubMed ID: 7906851
[TBL] [Abstract][Full Text] [Related]
35. Dopamine transporter mRNA: dense expression in ventral midbrain neurons.
Shimada S; Kitayama S; Walther D; Uhl G
Brain Res Mol Brain Res; 1992 May; 13(4):359-62. PubMed ID: 1352613
[TBL] [Abstract][Full Text] [Related]
36. Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and humans.
Zheng Y; Watakabe A; Takada M; Kakita A; Namba H; Takahashi H; Yamamori T; Nawa H
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):701-6. PubMed ID: 19336245
[TBL] [Abstract][Full Text] [Related]
37. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization.
German DC; Manaye K; Smith WK; Woodward DJ; Saper CB
Ann Neurol; 1989 Oct; 26(4):507-14. PubMed ID: 2817827
[TBL] [Abstract][Full Text] [Related]
38. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
[TBL] [Abstract][Full Text] [Related]
39. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
40. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
Adelbrecht C; Agid Y; Raisman-Vozari R
Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
